Innovus Pharmaceuticals (INNVD) News Today → LEAKED: Jeff Bezos' $330 Million Gamble (From Behind the Markets) (Ad) Free INNVD Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18, 2024 | wsj.comTRACON Pharmaceuticals Inc.May 13, 2024 | businesswire.comAldevron Announces Strategic Partnership with Acuitas TherapeuticsMay 9, 2024 | msn.comIdentiv, Inc. (NASDAQ:INVE) Q1 2024 Earnings Call TranscriptApril 24, 2024 | seekingalpha.comInovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High ValuationApril 16, 2024 | msn.comInovio Pharmaceuticals Stock Is Diving Today: What's Happening?April 11, 2024 | nasdaq.comSyros Pharmaceuticals, Inc. Common Stock (SYRS)April 10, 2024 | msn.comVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealApril 8, 2024 | marketwatch.comSupernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not ReadyApril 4, 2024 | marketwatch.comStocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNetMarch 28, 2024 | msn.comHow Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study ShowsMarch 28, 2024 | seekingalpha.comELDN Eledon Pharmaceuticals, Inc.March 27, 2024 | msn.comSanders calls for Novo Nordisk to slash Ozempic, Wegovy pricesMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Esperion on Growth Potential Post-FDA ApprovalMarch 25, 2024 | msn.comNovo Nordisk targets heart disease in $1.1 billion dealMarch 6, 2024 | markets.businessinsider.comINO Stock Earnings: Inovio Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023February 28, 2024 | marketwatch.comAmpio Pharmaceuticals Up 26% on Securities-Sale UpdatesFebruary 27, 2024 | markets.businessinsider.comThe Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 ExpertsFebruary 26, 2024 | msn.comiBio stock jumps on sale of preclinical PD-1 agonist antibody programFebruary 20, 2024 | msn.comIovance rallies nearly 40% on FDA approval, stock offeringFebruary 9, 2024 | bizjournals.comWexford pharmaceutical company expands antiviral initiativesFebruary 9, 2024 | msn.comNovo Nordisk Has a Weight-Loss Pill But Can’t Make It YetFebruary 8, 2024 | investing.comCitius Pharmaceuticals Inc (CTXR)February 7, 2024 | insidermonkey.comInnovAge Holding Corp. (NASDAQ:INNV) Q2 2024 Earnings Call TranscriptFebruary 5, 2024 | investing.comApellis Pharmaceuticals Inc (APLS)February 5, 2024 | msn.comNovo Nordisk Spends $11 Billion on Meeting Obesity Drug DemandFebruary 2, 2024 | uk.investing.comTRACON Pharmaceuticals Inc (TCON)January 29, 2024 | morningstar.comNovo Nordisk Earnings: High Expectations as the Firm Sprints Ahead In PharmaceuticalsJanuary 23, 2024 | investing.comSyros Pharmaceuticals Inc (SYRS)January 22, 2024 | finance.yahoo.comCold Relief Roll-On Market Projected to Surge at 8.7% CAGR, Reaching US$926.7 Million by 2030, Persistence Market ResearchJanuary 21, 2024 | morningstar.comARS Pharmaceuticals Inc SPRYJanuary 14, 2024 | nasdaq.comMove Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024December 6, 2023 | finance.yahoo.comCold Relief Roll On Market Set for Remarkable Growth: Expected Valuation of US$ 1,156.5 Million by 2033, CAGR at 8.3% | Future Market Insights, Inc.November 14, 2023 | markets.businessinsider.comPromising Biomarker Data and Optimal Dose Selection Drive Buy Rating for Acumen PharmaceuticalsNovember 4, 2023 | morningstar.comImpel Pharmaceuticals Inc IMPLNovember 2, 2023 | wsj.comTelcon RF Pharmaceutical Inc.October 27, 2023 | bizjournals.comLipella Pharmaceuticals closes on $2 million private placement offeringSeptember 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Maravai Lifesciences Holdings (MRVI)September 6, 2023 | reuters.comNovartis names new board member after international boss steps downSeptember 5, 2023 | markets.businessinsider.comWhere Olema Pharmaceuticals Stands With AnalystsAugust 15, 2023 | marketwatch.comInovio Pharmaceuticals Inc. stock falls Tuesday, underperforms marketAugust 9, 2023 | markets.businessinsider.comInovio Pharmaceuticals Inc. Q2 Loss decreases, beats estimatesAugust 4, 2023 | msn.comOppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform RecommendationJuly 25, 2023 | bizjournals.comBaltimore cannabis pharmaceutical company plans to go public on NasdaqJune 23, 2023 | benzinga.comSupernus Pharmaceuticals Entered Into Settlement And License Agreements With Apotex Inc. And Apotex Corp On June 21June 17, 2023 | finance.yahoo.comCosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.June 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Cigna (CI) and Jazz Pharmaceuticals (JAZZ)June 4, 2023 | fool.comBioMarin Pharmaceutical (NASDAQ: BMRN)May 18, 2023 | wsj.comRafarma Pharmaceuticals Inc.May 17, 2023 | seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Q1 2023 Earnings Call TranscriptMay 10, 2023 | markets.businessinsider.comHere's what to expect from Imprimis Pharmaceuticals's earnings report Get Innovus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNVD and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. INNVD Media Mentions By Week INNVD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INNVD News Sentiment▼0.000.76▲Average Medical News Sentiment INNVD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INNVD Articles This Week▼00▲INNVD Articles Average Week Get Innovus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: JAN News Today APLM News Today ONCT News Today VIRX News Today UBX News Today APRE News Today BIVI News Today INDP News Today APM News Today LSTA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:INNVD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
